73 related articles for article (PubMed ID: 38492276)
1. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
Sharma P; López-Tarruella S; García-Saenz JA; Ward C; Connor CS; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Del Monte-Millán M; Gonzalez-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortes J; Fuentes Rivera H; Bretel Morales D; Márquez-Rodas I; Perou CM; Wagner JL; Mammen JM; McGinness MK; Klemp JR; Amin AL; Fabian CJ; Heldstab J; Godwin AK; Jensen RA; Kimler BF; Khan QJ; Martin M
Clin Cancer Res; 2017 Feb; 23(3):649-657. PubMed ID: 27301700
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of Ki-67 in triple-negative breast cancer.
Wang W; Wu J; Zhang P; Fei X; Zong Y; Chen X; Huang O; He JR; Chen W; Li Y; Shen K; Zhu L
Oncotarget; 2016 May; 7(21):31079-87. PubMed ID: 27145269
[TBL] [Abstract][Full Text] [Related]
3. The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.
Castrellon AB; Pidhorecky I; Valero V; Raez LE
Oncol Rev; 2017 Mar; 11(1):324. PubMed ID: 28382189
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer: an update on neoadjuvant clinical trials.
Amos KD; Adamo B; Anders CK
Int J Breast Cancer; 2012; 2012():385978. PubMed ID: 22461984
[TBL] [Abstract][Full Text] [Related]
5. The Molecular Detection of Germline Mutations in the
Grigore LG; Radoi VE; Serban A; Mihai AD; Stoica I
Curr Issues Mol Biol; 2024 May; 46(5):4630-4645. PubMed ID: 38785549
[TBL] [Abstract][Full Text] [Related]
6. Platinum chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Breast; 2024 Jun; 75():103712. PubMed ID: 38492276
[TBL] [Abstract][Full Text] [Related]
7. Platinum-based chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
[TBL] [Abstract][Full Text] [Related]
8. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract][Full Text] [Related]
10. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis.
Saleh RR; Nadler MB; Desnoyers A; Meti N; Fazelzad R; Amir E
Cancer Treat Rev; 2021 Nov; 100():102283. PubMed ID: 34530283
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
Lin C; Cui J; Peng Z; Qian K; Wu R; Cheng Y; Yin W
Eur J Med Res; 2022 Oct; 27(1):201. PubMed ID: 36242046
[TBL] [Abstract][Full Text] [Related]
12. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
Zheng F; Du F; Wang W; Wang Y; Li M; Zhao J; Wang X; Yue J; Wang J; Yang Z; Cai R; Ma F; Fan Y; Li Q; Zhang P; Xu B; Yuan P
Breast Cancer Res Treat; 2022 Jan; 191(1):97-105. PubMed ID: 34648118
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Zhang L; Wu ZY; Li J; Lin Y; Liu Z; Cao Y; Zhang G; Gao HF; Yang M; Yang CQ; Zhu T; Cheng MY; Ji F; Li J; Wang K
Int J Cancer; 2022 Feb; 150(4):654-662. PubMed ID: 34591977
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
